Document Detail


The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection.
MedLine Citation:
PMID:  17642422     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To evaluate the height and weight patterns of children with chronic hepatitis B (CHB) with and without treatment. METHODS: Thirty-four patients with immunoactive CHB randomly assigned to receive interferon-alpha2a (IFN) (5 mIU/m2, 6 months, group I) or IFN (same dose and duration) plus lamivudine (4 mg/kg/day, 24 months) (group II). Fifteen immunotolerant patients (group III) were followed without any treatment. Height (Ht-SDS), weight (Wt-SDS) and growth velocity (GV-SDS) standard deviation scores were monitored for a total of 36 months. RESULTS: Ht-SDS was significantly lower in group II than in group I one year after completion of IFN treatment (p < 0.05). Wt-SDS was significantly higher in group I than the other groups two years after completion of IFN treatment (p < 0.05). In groups I and II, the percentage of children showing abnormal GV-SDS decreased once treatment was completed (p < 0.05). CONCLUSION: CHB does not have deleterious effects on height and weight. Although IFN treatment temporarily compromises weight gain and growth velocity, lamivudine does not have any additional adverse effect.
Authors:
Zarife Kuloğlu; Aydan Kansu; Fulya Demirçeken; Z Serap Arici; Merih Berberoğlu; Gönül Ocal; Nurten Girgin
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of pediatric endocrinology & metabolism : JPEM     Volume:  20     ISSN:  0334-018X     ISO Abbreviation:  J. Pediatr. Endocrinol. Metab.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-07-23     Completed Date:  2007-08-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508900     Medline TA:  J Pediatr Endocrinol Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  615-20     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology, Department of Pediatrics, Ankara University, School of Medicine, Ankara, Turkey. zarifekuloglu@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / administration & dosage,  adverse effects
Body Height / drug effects*
Body Weight / drug effects*
Child
Child, Preschool
Drug Therapy, Combination
Female
Growth Disorders / chemically induced*
Hepatitis B, Chronic / drug therapy*,  virology
Humans
Interferon-alpha / administration & dosage*,  adverse effects*
Lamivudine / administration & dosage*,  adverse effects*
Male
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 134678-17-4/Lamivudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Weight deficit at birth and Turner's syndrome.
Next Document:  Carbohydrate metabolism changes in cystic fibrosis.